Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

27 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Comparison of Clinically Relevant Oncolytic Virus Platforms for Enhancing T Cell Therapy of Solid Tumors.
Cervera-Carrascon V, Quixabeira DCA, Havunen R, Santos JM, Kutvonen E, Clubb JHA, Siurala M, Heiniö C, Zafar S, Koivula T, Lumen D, Vaha M, Garcia-Horsman A, Airaksinen AJ, Sorsa S, Anttila M, Hukkanen V, Kanerva A, Hemminki A. Cervera-Carrascon V, et al. Among authors: quixabeira dca. Mol Ther Oncolytics. 2020 Mar 19;17:47-60. doi: 10.1016/j.omto.2020.03.003. eCollection 2020 Jun 26. Mol Ther Oncolytics. 2020. PMID: 32322662 Free PMC article.
Tumor microenvironment remodeling by an engineered oncolytic adenovirus results in improved outcome from PD-L1 inhibition.
Cervera-Carrascon V, Quixabeira DCA, Santos JM, Havunen R, Zafar S, Hemminki O, Heiniö C, Munaro E, Siurala M, Sorsa S, Mirtti T, Järvinen P, Mildh M, Nisen H, Rannikko A, Anttila M, Kanerva A, Hemminki A. Cervera-Carrascon V, et al. Oncoimmunology. 2020 May 22;9(1):1761229. doi: 10.1080/2162402X.2020.1761229. Oncoimmunology. 2020. PMID: 32923123 Free PMC article.
Adenovirus Armed With TNFa and IL2 Added to aPD-1 Regimen Mediates Antitumor Efficacy in Tumors Refractory to aPD-1.
Cervera-Carrascon V, Quixabeira DCA, Santos JM, Havunen R, Milenova I, Verhoeff J, Heiniö C, Zafar S, Garcia-Vallejo JJ, van Beusechem VW, de Gruijl TD, Kalervo A, Sorsa S, Kanerva A, Hemminki A. Cervera-Carrascon V, et al. Among authors: quixabeira dca. Front Immunol. 2021 Jul 23;12:706517. doi: 10.3389/fimmu.2021.706517. eCollection 2021. Front Immunol. 2021. PMID: 34367166 Free PMC article.
Local therapy with an engineered oncolytic adenovirus enables antitumor response in non-injected melanoma tumors in mice treated with aPD-1.
Quixabeira DCA, Cervera-Carrascon V, Santos JM, Clubb JHA, Kudling TV, Basnet S, Heiniö C, Grönberg-Vähä-Koskela S, Anttila M, Havunen R, Kanerva A, Hemminki A. Quixabeira DCA, et al. Oncoimmunology. 2022 Jan 22;11(1):2028960. doi: 10.1080/2162402X.2022.2028960. eCollection 2022. Oncoimmunology. 2022. PMID: 35083096 Free PMC article.
Oncolytic adenovirus decreases the proportion of TIM-3+ subset of tumor-infiltrating CD8+ T cells with correlation to improved survival in patients with cancer.
Liikanen I, Basnet S, Quixabeira DCA, Taipale K, Hemminki O, Oksanen M, Kankainen M, Juhila J, Kanerva A, Joensuu T, Tähtinen S, Hemminki A. Liikanen I, et al. J Immunother Cancer. 2022 Feb;10(2):e003490. doi: 10.1136/jitc-2021-003490. J Immunother Cancer. 2022. PMID: 35193929 Free PMC article.
27 results